Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 25:15:245-255.
doi: 10.2147/CMAR.S400013. eCollection 2023.

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

Jing Zhang  1 , Yan Gu  1 , Baoan Chen  1
Affiliations
Review

Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL

Jing Zhang et al. Cancer Manag Res. .

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin's lymphoma (NHL). 30 ~ 40% of DLBCL patients were resistant to the standard R-CHOP regimen or recurrence after remission. It is currently believed that drug resistance is the main cause of the recurrence and refractory of DLBCL (R/R DLBCL). With the increased understanding of DLBCL biology, tumor microenvironment and epigenetics, some new therapies and drugs like molecular and signal pathway target therapy, chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, antibody drug-conjugate and tafasitamab have been used for R/R DLBCL. This article will review the drug resistance mechanism and novel targeted drugs and therapies of DLBCL.

Keywords: CAR-T therapy; CD47; NF-κB; antibody drug-conjugate; drug resistance; relapse and refractory DLBCL; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Drug resistance mechanisms and novel targeted drugs and treatments of DLBCL.
Figure 2
Figure 2
Schematic depiction of BCR signaling pathway and targeted drugs in DLBCL.
See this image and copyright information in PMC

References

    1. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103(1):275–282. doi:10.1182/blood-2003-05-1545 - DOI - PubMed
    1. Klener P, Klanova M. Drug resistance in non-Hodgkin lymphomas. Int J Mol Sci. 2020;21(6):2081. doi:10.3390/ijms21062081 - DOI - PMC - PubMed
    1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569 - DOI - PMC - PubMed
    1. Giacomelli AO, Yang X, Lintner RE, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50(10):1381–1387. doi:10.1038/s41588-018-0204-y - DOI - PMC - PubMed
    1. Fornecker LM, Muller L, Bertrand F, et al. Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma. Sci Rep. 2019;9(1):895. doi:10.1038/s41598-018-37273-4 - DOI - PMC - PubMed